Drug Trial Radar · NCT05127954
Long-term Extension Study to Assess Safety and Tolerability of Oral Ubrogepant Tablets for the Acute Treatment of Migraine in Pediatric Participants (Ages 6-17)
Last checked: Nov 19, 2026Latest source record: Jul 20, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Enrolling by invitation
Enrollment
1,200
Planned (sponsor's estimate)
Start
Jan 14, 2022
Primary completion
Jan 2028
Study completion Jan 2028
Sponsor
- Lead sponsor
- AbbVieAbbVie (ABBV)
- Sponsor type
- Industry
- First posted
- Nov 19, 2021
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Non randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 6 years, up to 17 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Migraine is a common neurological disorder typically characterized by attacks of throbbing, moderate to severe headache, often associated with nausea, vomiting, and sensitivity to light and sound. Migraine is extremely common and disabling in children. The purpose of this study is to evaluate long term safety and tolerability of ubrogepant in the acute treatment of migraine in pediatric participants. Ubrogepant is a drug approved for the acute treatment of migraine in adults. Pediatric participants (aged 6-17 years) with a history of migraine will be enrolled. Participants who completed the lead-in Study 3110-305-002, as well as those who were placebo responders and screen failed, will be eligible to enroll into this study. Around 1200 participants will be enrolled in the study at approximately 120 sites in the United States. Participants may receive ubrogepant oral tables to treat up to 8 migraine attacks of any intensity per month. There will be an option to take a second dose of study intervention (identical to initial dose), or rescue medication, starting 2 hours after the initial dose. The study duration will be up to 54 weeks. There may be higher treatment burden for participants in this trial compared to their standard of care. Participants will attend regular visits during the study at a hospital or clinic. The safety and tolerability of the treatment will be checked by medical assessments, blood tests, checking for adverse events and completing questionnaires.
Conditions
- Migraine
Interventions
UbrogepantDrug
Oral Tablet
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percentage of Participants with Adverse Events (AEs)Time frame: up to 54 weeks
- Percentage of Participants with Potentially Clinically Significant Clinical 12-lead Electrocardiogram (ECG)Time frame: Up to 54 Weeks
- Percentage of Participants with Potentially Clinically Significant Vital Sign ParametersTime frame: Up to 54 Weeks
- Percentage of Participants with Potentially Clinically Significant lab valuesTime frame: Up to 54 Weeks
- Percentage of with Participants with Suicidal Ideation or Suicidal BehaviorTime frame: Up to 54 Weeks
- Percentage of Participants with Change in Menstrual CycleTime frame: Up to 54 Weeks
- Change from baseline in Tanner staging scoreTime frame: Up to 54 Weeks
- Change From baseline in Behavior Rating Inventory of Executive Function (BRIEF 2) questionnaireTime frame: up to 54 weeks
Locations
113 sites in 2 countries. Site status is shown where the registry gives one.
Rehabilitation & Neurological Services /ID# 240054
Huntsville, Alabama
The Center for Clinical Trials - Saraland /ID# 239448
Saraland, Alabama
Preferred Research Partners /ID# 238979
Little Rock, Arkansas
Advanced Research Center /ID# 238967
Anaheim, California
Neuro Pain Medical Center /ID# 239135
Fresno, California
Alliance for Research Alliance for Wellness /ID# 233497
Long Beach, California
Children's Hospital Los Angeles /ID# 239446
Los Angeles, California
Excell Research, Inc /ID# 233495
Oceanside, California
Paradigm Clinical Research - San Diego /ID# 269611
San Diego, California
Lumos Clinical Research Center /ID# 239018
San Jose, California
Pacific Clinical Research Management Group /ID# 238503
Upland, California
Sunwise Clinical Research /ID# 238458
Walnut Creek, California
Children's Hospital Colorado - Aurora /ID# 239838
Aurora, Colorado
IMMUNOe Research Centers /ID# 240846
Centennial, Colorado
MCB Clinical Research Centers /ID# 240999
Colorado Springs, Colorado
New England Institute for Clinical Research /ID# 239019
Stamford, Connecticut
Emerson Clinical Research Inst /ID# 238455
Washington D.C., District of Columbia
Encore Medical Research of Boynton Beach LLC /ID# 248720
Boynton Beach, Florida
Gulf Coast Clinical Research Center /ID# 233335
Fort Myers, Florida
Sarkis Clinical Trials /ID# 233493
Gainesville, Florida
Northwest Florida Clinical Research Group, LLC /ID# 244396
Gulf Breeze, Florida
A.G.A Clinical Trials /ID# 238409
Hialeah, Florida
Encore Medical Research /ID# 247463
Hollywood, Florida
Advanced Research Institute of Miami /ID# 240712
Homestead, Florida
Auzmer Research /ID# 241514
Lakeland, Florida
Columbus Clinical Services, Llc /Id# 238968
Miami, Florida
My Preferred Research LLC /ID# 239020
Miami, Florida
Neurology & Pain Medicine /ID# 241860
Miami, Florida
Medical Research Group of Central Florida /ID# 240711
Orange City, Florida
Clinical Associates of Orlando, LLC /ID# 272623
Orlando, Florida
Suncoast Clinical Research - Palm Harbor /ID# 233535
Palm Harbor, Florida
Asclepes Research Centers - Spring Hill /ID# 231872
Spring Hill, Florida
University of South Florida- Neuroscience Institute /ID# 233420
Tampa, Florida
Encore Medical Research - Weston /ID# 248335
Weston, Florida
Pediatric Neurology and Epilepsy Specialists /ID# 233336
Winter Park, Florida
Global Research Associates /ID# 243504
Atlanta, Georgia
Rare Disease Research, LLC /ID# 238833
Atlanta, Georgia
Clinical Integrative Research Center of Atlanta (CIRCA) /ID# 238852
Atlanta, Georgia
Coastal Georgia Child Neurology /ID# 240845
Brunswick, Georgia
CenExcel iResearch LLC /ID# 239832
Decatur, Georgia
Showing 40 of 113 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.